Targeted delivery for liver cancer treatment

Projektinformationen

HEPTAG EXCHANGE

ID Finanzhilfevereinbarung: 295218

Abgeschlossenes Projekt

Startdatum 1 Januar 2012

Enddatum 31 Dezember 2015

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 105 001,00

EU-Beitrag € 105 000,00

Koordiniert durch

UNIVERSITY OF WOLVERHAMPTON
United Kingdom

Ziel

The Liver cancer drugs market is expected to become an active ground for competition in the future. According to recent market analysis, the liver cancer market in 2009 was valued at approximately US$0.4bn indicating a growth rate of 27.1% between 2001 and 2009. It is estimated that the liver cancer market in 2017 will be $1.2bn with a compound annual growth rate (CAGR) of 15.5% between 2009 and 2017. The growth of the liver cancer market is driven by the growth of the aging population, the greater access to medical care in the emerging new economic regions like China, and the innovative therapies such as targeted therapy

In this project target delivery for liver cancer treatment using biomarker functionalized vehicles is planned. Due to the lack of the needed expertise in one centre or region a consortium is formed. The consortium focuses on the development of nano-vehicle materials for targeted delivery and the relevant practices towards in vitro level of understanding of the effect of the delivery systems on cancer cell treatment. In this consortium, four work packages (WPs) are formed, namely, WP-1: Pharmaceutical materials; WP-2: Formulations; WP-3: Cancer cell imaging; and WP-4: Cancer cell treatment. To support this consortium, biomarkers will be selected from the available products in terms of the functionality of the biomarkers. The consortium comprises 4 partners (2 from EU, 1 from China, and 1 from USA), who are centers of excellence in their unique areas of expertise: Sichuan for preparation of functional polymersomes, Navarra for drug formulations, FIU for cancer cell imaging, and UoW for cancer cell treatment. Most importantly is the development of novel liver cancer therapy, fostering strategic collaborations between EU and China and knowledge transfer and dissemination through staff mobility.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › liver cancer

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2011-IRSES - Marie Curie Action "International Research Staff Exchange Scheme"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2011-IRSES
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IRSES - International research staff exchange scheme (IRSES)

Koordinator

UNIVERSITY OF WOLVERHAMPTON

Kontakt Verwaltung

James Zheng Gui Tang (Dr.)

• EU-Beitrag: € 63 000,00
• Adresse: WULFRUNA STREET ; WV1 1LY Wolverhampton ; Vereinigtes Königreich
• Region: West Midlands (England) › West Midlands › Wolverhampton
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten

Beteiligte (1)

UNIVERSIDAD DE NAVARRA

Spanien

Kontakt Verwaltung

Iñigo Uriarte Pueyo (Dr.)

• EU-Beitrag: € 42 000,00
• Adresse: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL ; 31080 Pamplona
• Region: Noreste › Comunidad Foral de Navarra › Navarra
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten